Department of Thyroid, Parathyroid, Breast, and Hernia Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China.
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China.
Endocrine. 2022 Feb;75(2):495-507. doi: 10.1007/s12020-021-02906-8. Epub 2021 Oct 26.
Distant metastasis from papillary thyroid microcarcinoma (PTMC) is extremely rare and the long-term outcomes and independent prognostic factors remain unclear. The present study aimed to investigate clinicopathological characteristics and evaluate the long-term outcomes and prognostic factors of PTMC patients with distant metastases (DM) who underwent surgery and radioactive iodine (I) treatment.
We retrospectively reviewed the medical records of 13,441 patients with thyroid cancer (including 1697 cases with PTMC) who underwent I treatment at our institution between January 2008 and December 2019. PTMC patients with distant metastases with sufficient clinical follow-up data were enrolled in this cohort study. The overall survival (OS) and progression-free survival (PFS) were analyzed by the Kaplan-Meier method and the prognostic factors were assessed by Cox proportional hazards.
Thirty-three PTMC patients with DM were enrolled in this study. The median follow-up was 75 months (range: 5-151 months). The 5-year and 10-year OS rates were 96.97 and 81.41%, respectively, and the 5-year and 10-year PFS rates were 90.46 and 69.68%, respectively. Multivariate analysis showed that male sex (P = 0.005), radioactive iodine refractory PTMC (P = 0.033), and symptomatic DM (P = 0.022) were significantly associated with worse 10-year PFS in PTMC patients with DM. No independent predictor related to poor 10-year OS was found in the present study.
The prognosis of PTMC patients becomes worse after the development of DM. Male sex, radioactive iodine refractory PTMC, and symptomatic DM were identified as independent factors associated with PFS.
甲状腺微小乳头状癌(PTMC)远处转移极为罕见,其长期结局和独立预后因素仍不清楚。本研究旨在探讨手术和放射性碘(I)治疗后发生远处转移(DM)的 PTMC 患者的临床病理特征,并评估其长期结局和预后因素。
我们回顾性分析了 2008 年 1 月至 2019 年 12 月在我院接受 I 治疗的 13441 例甲状腺癌患者(包括 1697 例 PTMC 患者)的病历。本队列研究纳入了有足够临床随访数据的 PTMC 伴远处转移患者。采用 Kaplan-Meier 法分析总生存期(OS)和无进展生存期(PFS),采用 Cox 比例风险模型评估预后因素。
本研究共纳入 33 例 PTMC 伴 DM 患者。中位随访时间为 75 个月(范围:5-151 个月)。5 年和 10 年 OS 率分别为 96.97%和 81.41%,5 年和 10 年 PFS 率分别为 90.46%和 69.68%。多因素分析显示,男性(P=0.005)、放射性碘难治性 PTMC(P=0.033)和有症状的 DM(P=0.022)与 DM 患者 10 年 PFS 较差显著相关。本研究未发现与 OS 不良相关的独立预测因素。
PTMC 患者发生 DM 后预后变差。男性、放射性碘难治性 PTMC 和有症状的 DM 是与 PFS 相关的独立因素。